Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fortress Biotech ( (FBIO) ) has shared an announcement.
On October 1, 2025, Fortress Biotech, Inc. announced that the U.S. Food and Drug Administration issued a complete response letter for their product CUTX-101 (copper histidinate). This development may impact the company’s operations and its positioning within the pharmaceutical industry, as regulatory feedback can influence product timelines and stakeholder expectations.
The most recent analyst rating on (FBIO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.
Spark’s Take on FBIO Stock
According to Spark, TipRanks’ AI Analyst, FBIO is a Neutral.
Fortress Biotech’s overall stock score is primarily impacted by its challenging financial performance, characterized by declining revenues and high leverage. However, positive technical indicators and a beneficial corporate event provide some support. The valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on FBIO stock, click here.
More about Fortress Biotech
Average Trading Volume: 748,624
Technical Sentiment Signal: Hold
Current Market Cap: $116M
Find detailed analytics on FBIO stock on TipRanks’ Stock Analysis page.